公开(公告)号：US12036213B2

公开(公告)日：2024-07-16

申请号：US17315667

申请日：2021-05-10

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/451 ,  A61K9/00 ,  A61K45/06 ,  A61P25/14 ,  A61P25/16 ,  A61K31/198

CPC classification number: A61K31/451 ,  A61K9/0053 ,  A61K45/06 ,  A61P25/14 ,  A61P25/16 ,  A61K31/198

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia.

公开(公告)号：US20230112948A1

公开(公告)日：2023-04-13

申请号：US17967415

申请日：2022-10-17

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61P25/00 ,  A61P25/24 ,  A61P25/22

Abstract: This invention provides a method of treating depression or anxiety in a human subject by administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230100072A1

公开(公告)日：2023-03-30

申请号：US17980590

申请日：2022-11-04

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61P31/14

Abstract: The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.

公开(公告)号：US11234973B2

公开(公告)日：2022-02-01

申请号：US16514167

申请日：2019-07-17

Applicant: PRILENIA NEUROTHERAPEUTICS LTD. ,  NATIONAL UNIVERSITY OF SINGAPORE ,  AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Michael Hayden ,  Mahmoud Abdulhossein Pouladi

IPC: A61K31/451 ,  A61K9/00 ,  A61P43/00 ,  A61K45/06

Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

公开(公告)号：US11141412B2

公开(公告)日：2021-10-12

申请号：US16535107

申请日：2019-08-08

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Malle Schmidt ,  Malle Pari ,  Marit Laos ,  Ants Maasalu ,  Kalle Kaljuste

IPC: A61K31/451 ,  C07D211/52 ,  C07D211/24 ,  C07D211/42 ,  G01N30/88

Abstract: This invention provides an isolated compound having the structure: or a salt thereof, processes for making the same and to compositions comprising pridopidine with these compounds.

公开(公告)号：US20210093622A1

公开(公告)日：2021-04-01

申请号：US17074901

申请日：2020-10-20

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael HAYDEN ,  Mahmoud Abdulhossein POULADI

IPC: A61K31/4453 ,  A61K9/00 ,  A61P25/24 ,  A61K9/48 ,  A61P25/22

Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject.

公开(公告)号：US10799492B2

公开(公告)日：2020-10-13

申请号：US16133192

申请日：2018-09-17

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Clas Sonesson

IPC: A61K31/451 ,  C07D211/24 ,  C07D211/32 ,  C07B59/00

Abstract: The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease.In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.

公开(公告)号：US10603311B2

公开(公告)日：2020-03-31

申请号：US15052368

申请日：2016-02-24

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Ilya Bezprozvanny ,  Merav Bassan ,  Michael Hayden

IPC: A61K31/451 ,  C07D211/24 ,  C07D211/52 ,  C07D211/42

Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject.The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.

公开(公告)号：US20240398778A1

公开(公告)日：2024-12-05

申请号：US18814529

申请日：2024-08-25

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN

IPC: A61K31/451 ,  A61K9/00 ,  A61P25/14

Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

公开(公告)号：US20240041855A1

公开(公告)日：2024-02-08

申请号：US18491871

申请日：2023-10-23

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Daniella LICHT ,  Ioana Lovinger ,  Laura Yehudit Guilatt ,  Merav Bassan

IPC: A61K31/451 ,  A61K9/16 ,  A61K9/20

CPC classification number: A61K31/451 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2068

Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.